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Abstract
Background: In healthy, HIV seronegative, CMV seropositive adults, a large proportion of T cells are CMV-specific. High-level
CMV-specific T cell responses are associated with accelerated immunologic aging (‘‘immunosenesence’’) in the elderly
population. The impact of untreated and treated HIV infection on the frequency of these cells remains undefined.
Methodology/Principal Findings: We measured the proportion of CD4+ and CD8+ T cells responding to CMV pp65 and IE
proteins was measured using flow cytometry in 685 unique HIV seronegative and seropositive individuals. The proportion of
CMV-specific CD8+ T cells was consistently higher in the HIV-seropositive subjects compared to the HIV-seronegative
subjects. This HIV effect was observed even in patients who lacked measurable immunodeficiency. Among the HIV-
seropositive subjects, CMV-specific CD8+ T cell responses were proportionately lower during recent infection, higher during
chronic untreated infection and higher still during long-term antiretroviral treated infection. The CD8+ T cell response to
just two CMV proteins (pp65 and IE) was approximately 6% during long-term therapy, which was over twice that seen in
HIV-seronegative persons. CMV-specific CD4+ T cell responses followed the same trends, but the magnitude of the effect
was smaller.
Conclusions/Significance: Long-term successfully treated HIV infected patients have remarkably high levels of CMV-specific
effector cells. These levels are similar to that observed in the elderly, but occur at much younger ages. Future studies should
focus on defining the potential role of the CMV-specific inflammatory response in non-AIDS morbidity and mortality,
including immunosenescence.
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Introduction
Cytomegalovirus (CMV) is a highly prevalent herpesvirus
infection capable of causing end-organ disease in the setting of
HIV-associated immunodeficiency. CMV infection has also been
shown to be an independent factor associated with non-CMV end
organ disease progression in untreated HIV disease [1,2,3,4,5,6]
and may negatively affect outcomes even in presence of successful
antiretroviral therapy [7,8]. Among a large cohort of treated
patients, CMV viremia was associated with higher risk of
mortality, independent of plasma HIV RNA level and CD4+ T
cell counts [7]. Our group has recently shown that elevated CMV-
specific immune responses are strongly associated with the level of
atherosclerosis in HIV-infected, CMV-seropositive individuals [9],
which may provide a mechanistic explanation for the consistent
association between CMV and atherosclerosis in immunodeficient
states [10].
There is also substantial evidence indicating that chronic CMV
infection is associated with accelerated immunologic aging, or
immunosenescence, in the elderly population [11,12,13,14,15]
and in thymectomized younger adults [16]. Perhaps the strongest
correlate of immunosenescence is the oligoclonal expansion of
memory effector CD8+ T cells. These CD8+CD282 cells have
limited ability to proliferate and are resistant to apoptosis [17,18].
CMV-seropositive adults over the age of 65 to 70 have a much
greater expansion of these CD282 cells than age-matched CMV-
serogenegative controls (many of these cells reflect the oligoclonal
expansion of CMV-specific T cells) [12,19,20,21,22,23,24]. The
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research; however, it has already been shown that CMV-
seropositive older persons are less likely to respond to vaccines
than age-matched, CMV-seronegative persons [13] and that
CMV-associated changes in the immune system are highly
predictive of early mortality among older persons [22,25]. Finally,
CMV seropositivity has been associated with higher rates of
neurocognitive decline amongst the elderly [26,27], while CMV
reactivation in critically ill older patients predicts early mortality
[15].
Despite the apparent importance of CMV infection in HIV
infection, relatively little is known about CMV-specific T cell
responses throughout the course of acute and chronic untreated
disease, as well as during the course of long-term treated HIV
disease. Methods have recently been developed and validated for
high-throughput flow cytometric evaluation of antigen-specific T
cell immune responses. When this approach was applied to a
cohort of HIV seronegative CMV seropostive adults, it was
demonstrated that approximately 5 to 10% of the circulating
CD4+ and CD8+ T cell population recognize CMV in an antigen-
specific manner [28]. A small subset of otherwise healthy adults
may maintain over time an even higher levels of CMV-specific T
cells [29]. Among HIV infected individuals, those on long-term
HAART tend to have higher CMV-specific T cells responses then
those who have progressive disease, or who have active CMV
disease [28,30,31,32,33]. Long-term antiretroviral treated patients
may also have higher levels of more differentiated CMV-specific
CD8+ T cells than HIV negative individuals [34]. However, to
our knowledge, no study has sought to assess in a comprehensive
manner using large numbers of individuals the epidemiology of
CMV-specific T cell immunity across the entire spectrum of HIV
disease (including acute and chronic disease as well as untreated
and treated disease). Also, no prior study was large enough to
consider in the analysis other factors known to influence CMV
specific immunity (e.g., age).
Here, we report a comprehensive survey of CMV-specific T
cells in a large cohort of both HIV uninfected and infected adults.
HIV-seropositive patients from all disease stages were selected,
including those with acute disease, chronic antiretroviral untreated
disease and long-term antiretroviral treated disease. For each of
the analyses, we measured the proportion of freshly obtained
CD4+ and CD8+ T cells that express high levels of interferon-c in
response to two of the most immunodominant CMV proteins [28]:
pp65, a structural protein expressed throughout the viral life cycle,
and the intermediate early (IE) protein.
Methods
Ethics Statement
This study was approved by the University of California, San
Francisco Committee on Human Research (CHR). All partici-
pants provided written informed consent.
Participants
HIV-infected participants were sampled from three prospective
cohort studies in San Francisco. The SCOPE project is a
prospective clinic-based cohort of chronically HIV-infected adults.
T cell studies were performed consecutively in 395 participants.
REACH is a community-based cohort of chronically HIV-infected
adults. A subset of 60 consecutive participants consented to
monthly adherence assessments and had immunophenotyping of
T cells performed once during this time. The Options project is a
cohort of individuals with evidence of acute or recent HIV-1
infection [35]. CMV specific T cell responses were performed in
147 consecutive participants who enrolled in the study. Subjects
were stratified into four unique groups based on their clinical
status at the time peripheral blood was obtained for this study: (1)
recent untreated HIV infection (defined as having an estimated
duration of infection of less that 180 days), (2) chronic untreated
HIV infection, (3) chronic antiretroviral treated infection with
undetectable plasma HIV RNA levels (,50 to 75 copies RNA/
mL) and (4) chronic antiretroviral treated infection with detectable
plasma HIV RNA levels.
As controls, HIV-uninfected but at-risk participants were
sampled from a cohort of individuals who had received post-
exposure prophylaxis following a sexual exposure to HIV. Forty-
six HIV-seronegative individuals had immunophenotyping per-
formed at a visit 48 weeks following their receipt of post-exposure
prophylaxis. An additional 37 HIV-seronegative adults responded
to poster and internet advertisements looking for HIV seronegative
volunteers, and were recruited into the SCOPE cohort [9].
For all of the cohorts involved, participants were selected in
consecutive manner, and began when funding was made available
for these studies, and stopped when funding was no longer
available. Hence, there were no a priori criteria used to select the
specimens.
CMV-Specific T Cell Responses
All T cell studies were performed using freshly collected
peripheral blood. The same method and the same laboratory
were used for all study participants [36]. For both pp65 and IE
responses, a pool of 15 amino acid peptides (each overlapping by
11 amino acids) from each protein was synthesized. Fresh whole
blood was then stimulated with these peptide pools in the presence
of brefeldin A, an inhibitor of intracellular transport that blocks
the extracellular secretion of cytokines. Non-stimulated and
superantigen staphylococcal enterotoxin B (SEB)-stimulated sam-
ples were used as negative and positive controls, respectively. Cells
were then fixed and permeabilized before incubation with
fluorescein isothiocyanate (FITC)-conjugated anti-IFN-c, phyco-
erythrin (PE)–conjugated anti-CD69, phycoerythrin–cyanin red
5.1 (PC5)–conjugated anti-CD4, and allophycocyanin (APC)-
conjugated anti-CD3. The fraction of activated, cytokine-secreting
(CD69+IFN-c+) CD4+ and CD8+ T lymphocytes was determined
by flow cytometry using a Becton Dickinson FACS Calibur. The
lymphocyte gate was determined by forward and side scatter.
In our primary analysis, we focused only on those cells that
stained brightly for IFN-c (to reduce the number of false positive
responses). These ‘‘IFN-c bright’’ events were defined as CD69+
IFN-c+ events that fell 3 decades above the IFN-c-negative
population in non-stimulated controls, as previously described
[37]. All measurements were background corrected. We also
measured IL2 and IFN-c production in response to pp65 and IE
in a subset of subjects, standard gating was used for both cytokines.
Statistical Analylsis
Wilcoxon rank sum tests were used to compare the percent
CMV-specific T cells between groups. Unadjusted associations
between continuous variables were assessed with Spearman’s rank
order correlation coefficients. Adjusted associations were assessed
with linear regression, transforming continuous variables and
calculating standard errors with heteroskedasticity-consistent
covariance matrix estimators when necessary to satisfy model
assumptions [38]. Age, gender, CD4+ T cell count, plasma HIV
RNA level, and disease stage (acute versus chronic, treated versus
not treated) were all considered potential confounders in
multivariable models, but were removed in a stepwise manner if
their inclusion changed the beta coefficient of the primary
HIV and CMV-Specific T Cells
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role of influential observations were assessed for each regression
analysis.
Results
A total of 685 unique individuals were included in this study
(Table 1). Eighty-three of these were HIV seronegative and most
of them were men (n=75) who were CMV seropositive (n=60).
The remaining 602 subjects represented a broad spectrum of
treated and untreated HIV infection: 77 were antiretroviral-
untreated and recently infected (estimated infection duration of
less than 180 days); 176 were antiretroviral-untreated and
chronically infected (median CD4 count of 525 cells/mm
3); 203
were antiretroviral-treated and had undetectable plasma HIV
RNA levels (median CD4 of 503 cells/mm
3); and 146 were
antiretroviral-treated had a detectable plasma HIV RNA level
(median CD4 count of 277 cells/mm
3). Of the 332 HIV-infected
participants whose CMV antibody status was tested, only 4 (1.2%)
were CMV seronegative. The median ages of the HIV-
seronegative and HIV-seropositive subjects were 40 and 44 years.
CMV Specific T Cell Responses in CMV-Seropositive and
Seronegative Individuals
To understand the relationship between CMV-specific T cell
responses and CMV serology, the frequency of pp65-specific IFN-
c bright CD4+ and CD8+ T cell responses was compared between
HIV seronegative/CMV-seronegative (n=23) subjects and the
HIV seronegative/CMV-seropositive subjects (n=60). No CMV-
seronegative individual had detectable pp65-specific CD4+ and
CD8+ T cell responses above 0.05%, while the vast majority of
CMV-seropositive individuals had detectable responses above
these levels (Table 2 and Figure 1). The differences were significant
for both CD4+ and CD8+ CMV-specific T cells (p,0.0001 for
each pair-wise comparison between CMV-seronegative and
seropositive groups). Each of the four HIV-seropositive, CMV-
seronegative participants had no or only very low-levels of pp65-
specific T cell responses.
For all of the following analyses, we restricted the HIV-
seronegative subset to those who were known to be CMV-
seropositive. Since 98.8% of our HIV-infected participants with
CMV antibody data were seropositive, we included in the
following analysis all HIV subjects who were known to be CMV-
seropositive, as well as the additional subjects for whom the CMV
sero-status was not known. Notably, the vast majority of subjects
without CMV antibody data had clear evidence of CMV
infection based on their pp65-specific T cell responses. For
example, all confirmed CMV-seronegative subjects in our study
had a background corrected pp65-specific CD8+ Tc e l l
interferon-c response of ,0.03%, while only 16 of the 277
evaluable subjects without CMV antibody data had CD8+ Tc e l l
responses below this level (and 8 of these 16 had much stronger
pp65 specific CD4+ T cell response than the confirmed CMV-
seronegative subsets).
Impact of Recent and Chronic Untreated HIV Infection on
CMV Specific T Cell Responses
We next addressed the question of whether HIV infection is
associated with an altered CMV-specific T cells response. As
compared to the CMV-seropositive, HIV-seronegative group,
untreated participants with a recent HIV infection (n=77) had a
higher median frequency of pp65-specifc IFN-c bright CD8+ T
cells (0.31% vs. 0.67%, respectively, P=0.02) and a similar
median frequency of pp65-specifc IFN-c bright CD4+ T cells
(0.15% vs. 0.22%, P=0.15; Figure 2).
The 178 untreated, chronically HIV-infected participants had
even higher median frequencies of pp65-specifc IFN-c bright
CD8+ T cells (median 0.93%) and pp65-specifc IFN-c bright
CD4+ T cells (median 0.48%) (P,0.001 for the comparison of
both CD8+ and CD4+ T cell responses between the HIV-
seronegative subjects and the chronically infected subjects).
The absolute number of pp65-specific CD8+ T cells was
significantly elevated in both HIV-seropositive groups versus the
HIV-seronegative group (P,0.001 for each pairwise comparison;
data not shown). The absolute number of pp65-specific CD4+ T
cells was also slightly elevated among the two HIV-seropositive
groups compared to the HIV-seronegative group.
CMV-Specific T Cell Responses Are Higher in
Antiretroviral Treated Persons
We next studied 203 antiretroviral-treated subjects who had
undetectable plasma HIV RNA levels. The median pp65-specific
IFN-c-bright CD8+ T cell response in this group was 1.7% (IQR
0.6 to 3.5%) and the median CD4+ response was 0.25% (IQR
0.10 to 0.74%). These responses were higher than those observed
in the HIV-seronegative, CMV-seropositive group (P,0.0001 for
CD8+ T cell responses between the two groups and P=0.06 for
the CD4+ T cell responses between the two groups). These
responses were also higher than those observed in the group of
chronic untreated participants (P=0.0004 for CD8+ T cell
responses between the two groups and P=0.02 for the CD4+ T
cell responses between the two groups).
Table 1. Baseline characteristics.
HIV2
CMV2
HIV2
CMV+
Acute/recent
HIV infection
(,180 days)
Chronic,
untreated
HIV infection
Antiretroviral-
treated
(undetectable
viral load)
Antiretroviral-
treated
(detectable viral
load)
Number 23 60 77 176 203 146
Age (years) 40 (30–46) 39.2 (34.5–45.8) 35.9 (30.5–41.1) 43.8 (38.1–49.8) 45.1 (39.3–51.9) 46.7 (42.3–52.4)
Gender (% female) 13% 8% 4% 22% 8% 15%
CD4+ T cell count (cells/mm
3) NA 948 (689–1058) 578 (480–722) 525 (349–764) 503.5 (329–752) 278 (171–437)
CD8+ T cell count (cells/mm
3) NA 491 (324–647) 850 (630–1139) 942 (692–1279) 889 (619–1182) 1067 (741–1476)
Plasma HIV RNA (log10 copies/mL) NA NA 4.55 (3.83–4.93) 2.92 (1.88–4.36) 1.88 (1.88–1.88) 3.53 (2.64–4.33)
NOTE. Median values and interquartile ranges are shown unless otherwise noted.
doi:10.1371/journal.pone.0008886.t001
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detectable viremia (the majority of these subjects were known
to have an extensive history of drug-resistant viremia, as
previously described [37]). The pp65-specific responses in this
group were comparable to those observed in the treated subjects
who had undetectable viremia (median values of 1.38% and
0.19% pp65-specific CD8+ and CD4+ T cell response,
respectively).
Impact of Disease State on IE-Specific T Cell Responses
The intermediate early (IE) protein-specific T cells responses
were obtained all 83 HIV-seronegative individuals (60 of whom
were CMV seropositive) as well as on 20 subjects who had chronic
untreated HIV infection and 60 subjects who were on antiretro-
viral therapy and had an undetectable plasma HIV RNA level. As
expected, the IE-specific responses were higher in the HIV-
seronegative, CMV-seropositive subjects than in the HIV-
seronegative, CMV-seronegative subjects (P,0.0001 for both
CD4 and CD8 responses).
The effect of antiretroviral-treated HIV on IE-specific
response was similar to that observed with pp65 (Figures 3A
and 3B). The median proportion of IE-specific IFN-c-bright
CD4+ T cells was 0.02% in the HIV-seronegative/CMV-
seropositive, 0.03% in the chronic, untreated subjects, and
0.05% in antiretroviral treated, fully suppressed subjects
(P=0.009 for HIV negative vs. treated HIV). The median
proportion of IE-specific IFN-c-bright CD8+ T cells was 0.13%
in the HIV-seronegative/CMV-seropositive subjects, 0.11% in
the chronically infected, untreated subjects, and 0.62% in the
antiretroviral treated, fully suppressed subjects (P=0.001 for
HIV seronegative vs. treated HIV).
Impact of Disease State on pp65- and IE-Specific IFN-c
and IL2 T Cell Responses
Multi-functional (IFN-c and IL2) responses to pp65 and IE
were also measured in a subset of subjects (21 subjects who were
CMV-seropositive/HIV-seronegative, 20 subjects who had
chronic untreated HIV infection and 60 subjects who were on
Table 2. CMV-specific T cell responses in HIV uninfected and infected adults.
HIV2
CMV2
HIV2
CMV+
Acute/recent
HIV infection
(,180 days)
Chronic,
untreated
HIV infection
Antiretroviral-
treated
(undetectable
viral load)
Antiretroviral-
treated
(detectable
viral load)
pp65-specific interferon-c-bright
CD4+ T cells (%)
0.00 (0–0.01) 0.15 (0.06–0.61) 0.22 (0.11–0.49) 0.48 (0.13–1.17) 0.25 (0.1–0.74) 0.19 (0.05–0.58)
pp65-specific interferon-c-bright
CD8+ T cells (%)
0.00 (0–0.01) 0.31 (0.14–1.09) 0.67 (0.28–1.43) 0.93 (0.27–2.2) 1.67 (0.57–3.46) 1.38 (0.55–3.37)
IE-specific interferon-c-bright
CD4+ T cells (%)
0.00 (0–0.01) 0.02 (0–0.05) 0.02 (0–0.07) 0.04 (0.01–0.1) 0.03 (0–0.06)
IE-specific interferon-c-bright
CD8+ T cells (%)
0.00 (0–0) 0.13 (0.02–0.86) 0.11 (0.03–0.39) 0.62 (0.20–2.5) 0.20 (0.04–0.85)
pp65- and IE- interferon-c/IL2
CD4+ T cells (%)
0.06 (0.02–0.14) 0.24 (0.13–0.8) 0.52 (0.23–1.58) 0.70 (0.33–1.57) 0.36 (0.24–1.7)
pp65- and IE- interferon-c/IL2
CD8+ T cells (%)
0.03 (0.01–0.06) 2.06 (0.81–3.51) 1.73 (0.82–3.17) 4.67 (2.36–9.11) 2.97 (1.05–4.37)
NOTE. Median values and interquartile ranges are shown. All subjects contributed pp65-specific IFN-c-bright data (n=685), while only a subset contributed pp65 and IE
data (see text). IE data were not available from the recently infected subjects. The combined pp65 and IE interferon-c/IL2 data reflect the sum of all possible response
(IFN-c alone, IL2 alone and IFN-c/IL2) to each of the CMV protein.
doi:10.1371/journal.pone.0008886.t002
Figure 1. The distribution of percent of CMV-specific T cells in CMV-seronegative and CMV-seropositive, HIV-uninfected subjects.
doi:10.1371/journal.pone.0008886.g001
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levels) (Figure 3). In general, the pp65-specific responses were
higher than the IE-specific responses, as previously shown [31].
This was true for both CD4+ and CD8+ Tc e l lp o p u l a t i o n s .
Also, most responding cells made either IFN-c alone or IFN-c
and IL2 (cells producing IL2 only were rare). The only
Figure 2. The distribution of pp65 IFN-c-bright CD4+ and CD8+ T cell responses (background corrected) in four unique groups: (1)
HIV-seronegative, CMV-seropositive, (2) acute and recent untreated HIV infection, (3) established chronic untreated HIV infection,
and (4) antiretroviral-treated infection with undetectable plasma HIV RNA levels.
doi:10.1371/journal.pone.0008886.g002
Figure 3. The distribution of the CMV-specific CD4+ and CD8+ T cell responses (background corrected) in three unique groups: (1)
HIV-seronegative, CMV-seropositive, (2) established chronic untreated HIV infection, and (3) antiretroviral-treated infection with
undetectable plasma HIV RNA levels. The IE IFN-c-bright levels are shown in panel A (CD4+ T cells) and panel B (CD8+ T cells). The combined
pp65 and IE IFN-c/IL2 data are shown in panels C (CD4+ T cells) and panel D (CD8+ T cells). The data in panels C and D reflect the sum of all possible
response (IFN-c alone, IL2 alone, or IFN-c/IL2) to each of the CMV proteins. Standard gating was used for dual cytokine data.
doi:10.1371/journal.pone.0008886.g003
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the vast majority of cells made IFN-c alone.
To enumerate as many of CMV-specific cells as possible, we
combined the all of the pp65 and IE specific responses (i.e, IFN-c
only, IL2 only, IFN-c and IL2 populations were summed)
(Figures 3). The mean combined CD8+ T cells responses for
these two cytokines against these two CMV proteins were 2.7, 2.4,
and 6.0% in HIV-seronegative/CMV-seropositive subjects,
chronic untreated subjects and long-term treated groups, respec-
tively (P=0.002 for HIV-negative vs. antiretroviral-treated, and
P=0.0008 for chronic untreated vs. antiretroviral treated).
CMV-Specific T Cell Responses Are Elevated Before the
Onset of Immunodeficiency
Theoretically, HIV-associated immunodeficiency may result in
increased levels of CMV replication and this in turn could induce
increased levels of CMV-specific T cell responses. To determine if
CMV-specific T cell responses were elevated before the onset of
immunodeficiency, we identified those study participants who
were antiretroviral-untreated and had at the time of the analysis a
peripheral CD4+ T cell count greater than 500 cells/mm
3
(n=146). The pp65-specific CD4+ T cell response in these
presumably immunocompetent individuals was 0.32%, which was
significantly higher than that found in CMV-seropositive, HIV-
seronegative adults (median 0.15%, P=0.009). The pp65-specific
CD8+ T cell response was 0.62%, which was also higher than that
in CMV-seropositive HIV-seronegative adults (median 0.31%,
P=0.02).
Predictors of CMV-Specific T Cell Responses in Untreated
and Treated HIV Infection
We next assessed the factors associated with CMV-specific
responses, focusing on the pp65 IFN-c bright data as this was the
only outcome available on the entire cohort. In unadjusted
analysis, the most consistent predictor of both the pp65-specific
CD4+ and CD8+ T cell response was age, although the strength of
these associations was generally weak. For example, amongst the
long-term antiretroviral treated patients with undetectable viral
loads, age was positively correlated with both pp65-specific CD4+
T cells responses (rho=0.26, P=0.0001) and CD8+ T cell
responses (rho=0.24, P=0.0004).
The peripheral CD4+ T cell count was negatively associated
with the pp65-specific T cell responses, but again the associations
were weak. Amongst the untreated cohort, CD4+ T cell counts
were negatively associated with the pp65-specific CD8+ T cell
responses (rho=20.27; P=0.0002). Weak, marginally significant
negative associations were observed among the treated individuals
who had undetectable viremia. There were no consistent
associations between plasma HIV RNA levels and pp65-specific
T cell responses.
We next performed multivariable linear regression to determine
what role age and other factors may have had in our comparisons
between groups (Tables 3–6). After adjustment for age, CD4+ T
cell count, and gender, the long-term antiretroviral-treated
subjects with undetectable viremia had a higher proportion of
pp65-specific CD8+ T cell responses than the HIV-seronegative,
CMV-seropositive subjects (P=0.009). After controlling for these
same factors, there was no difference in the pp65-specific CD4+ T
cell responses (P=0.46). The differences in pp65-specific T cell
responses between the antiretroviral-treated subjects (with unde-
tectable viremia) and the untreated subjects remained significant
after controlling for age, gender and CD4+ T cell count (P=0.008
for adjusted comparison of pp65-specific CD8+ T cells response
and P=0.005 for the adjusted comparison of pp65-specific CD4+
T cell responses).
Discussion
Using our large cohort of HIV -seropositive persons in various
stages of HIV infection, as well as a large cohort of HIV-
seronegative persons, we investigated the impact of HIV and its
treatment on CMV-specific T cell responses. Our work was driven
in part by emerging data that chronic CMV infection can have
profound detrimental effects on immune function as people age
[39,40]. When all data across all cohorts are considered, a
complex but consistent story emerges. Early HIV infection was
associated with higher frequencies of pp65-specific CD8+ T cell
responses (as compared to HIV seronegatives), confirming
previous reports [41,42]. This occurred before the onset of
measurable immunodeficiency. CMV-specific CD8+ T cell
responses were higher in chronic untreated HIV infection
compared to recent HIV infection. Surprisingly, these responses
were even higher among antiretroviral-treated individuals (on
average, 6% of the peripheral CD8+ T cells from these subjects
produced IFN-c and/or IL-2 in response to CMV, a finding even
more remarkable when considering that we measured responses
against only two of the over 200 CMV-encoded proteins). The
CMV-specific CD4+ T cell responses follow similar trends. These
data indicate that CMV infection has a profound effect on the
adaptive immune response during untreated HIV disease and this
effect is accentuated by long-term administration of combination
antiretroviral therapy.
It is now widely accepted that chronic CMV infection has
profound effects on the immune system in the very old. As
compared to elderly CMV seronegative adults, those who are
CMV seropositive have lower CD4/CD8 ratios, lower naı ¨ve T cell
numbers, higher frequencies of well differentiated CD8+CD282
Table 3. Percentage of pp65-specific interferon-c+ CD8+ T
cells in antiretroviral treated subjects with undetectable viral
loads and HIV seronegative subjects.
Coefficient P 95% CI
HIV 0.95 0.009 0.24 1.66
Age (per 10 years) 0.57 0.002 0.21 0.94
Female 20.19 0.83 21.95 1.57
CD4 (per 100 cells/mL 20.010 0.005 20.02 20.003
Constant 20.50 0.54 22.10 1.10
doi:10.1371/journal.pone.0008886.t003
Table 4. Percentage of pp65-specific interferon-c + CD4+ T
cells in antiretroviral treated subjects with undetectable viral
loads and HIV seronegative subjects.
Coefficient P 95% CI
HIV 20.12 0.46 20.43 0.20
Age (per 10 years) 0.32 0.004 0.10 0.53
Female 20.44 0.037 20.86 20.03
CD4 (per 100 cells/mL 20.005 0.009 20.009 20.001
Constant 20.29 0.54 21.22 0.64
doi:10.1371/journal.pone.0008886.t004
HIV and CMV-Specific T Cells
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8886memory cells and perhaps a smaller T cell repertoire and [22,25].
Based on extensive experimental data, a theoretical model has
emerged that could provide an mechanistic basis for these
observations [39,40,43,44,45,46]. Specifically, chronic viral infec-
tions that establish latency (e. g., the herpes viruses) cause
persistent antigenic stimulation to T cells. These T cells
continually expand in response to this proinflammatory environ-
ment, eventually forming a large population of well-differentiated,
apoptosis-resistant, virus-specific CD8+ T cells with limited
proliferative potential. These cells take up ‘‘immunologic space’’,
preventing the generation of new naı ¨ve and central memory cells
(a process that may be accentuated by the age-related decline in
thymic function [16,47]). Collectively, these change result in
accelerated immunologic aging, or ‘‘immunosenescence’’, which
in turn contributes to age-associated morbidities. Theoretically,
HIV-associated inflammation and HIV-associated thymic dys-
function may cause many of these same changes to the adaptive
immune system [43,48].
Although the rates of CMV end organ disease have dropped
dramatically since the introduction of combination antiretroviral
therapy, a number of studies indicate that CMV seropositivity
continues to be associated with significant morbidity and
mortality in the setting of chronic HIV infection. Most notably,
Griffiths and colleagues found that among patients with advanced
HIV disease (most of whom were on antiretroviral therapy),
plasma CMV DNA levels was strongly predictive of mortality [7].
Several mechanisms have been suggested, including the positive
effect that CMV and other herpes viruses may have on HIV
replication [49,50,51]. We favor an indirect effect of CMV on
outcome via the strong proinflammatory role that CMV appears
to have in vivo [28]. Given the well-accepted role of inflammation
as key component of HIV associated immunopathogenesis
[52,53,54,55,56], it is reasonable to assume that CMV-associated
inflammation would have a largely detrimental effect on disease
outcomes.
The persistent CMV associated inflammatory response outlined
here is also notable for its magnitude. The levels of pp65-specific
interferon-gamma producing CD8+ T cells in our antiretroviral-
treated patients was comparable to that observed in very old HIV
seronegative persons (.85 years of age) [57]. On average, 6% of the
circulating CD8+ T cells in antiretroviral-treated patients recognize
either pp65 or IE peptides as defined by the production of
interferon-c and/or IL2. The total CMV specific T cell response is
almost certainly much greater since pp65 and IE reflect only one of
over 200 open reading frames in CMV, many of which are known
to be immunogenic [28]. Also, many antigen-specific T cells do not
make IFN-c and/or IL2 in response to ex-vivo peptide stimulation.
Assuming that the pp65- and IE- specific IFN-c/IL2 responses
makes up only a small fraction of the total CMV-specific T cell
responses (a reasonable assumption given that this has been clearly
demonstrated in HIV seronegative individuals [28]), then the overall
CMV-specific inflammatory response in antiretroviral-treated HIV
disease is likely to be enormous (since CMV-specific responses were
at least twice as high in our treated HIV infected patients than in the
HIV seronegative subjects, and since one comprehensive study of
healthy CMV-seropositive adults found that on average 10% of the
T cell population was CMV-specific [28], then it seems likely that
approximately 20% of all circulating CD8+ T cells in antiretroviral-
treated patients are directed at this single virus).
In summary, heightened CD8+ T cell activity directed against
CMV is observed in early HIV infection, persists at higher levels in
chronic untreated HIV infection, and is accentuated even further
upon administration of effective combination antiretroviral
therapy. Possible mechanisms for the very high frequencies of
CMV-specific T cells in antiretroviral-treated HIV disease include
sub-clinical CMV replication and/or a dysregulated and height-
ened immunologic response to a normal level of CMV replication
(perhaps as a consequence of loss of certain immunoregulatory
cells). The recent observation that CMV-specific CD4+ T cells
secrete large amounts of chemokines that protect these cells from
HIV entry may also be a contributing factor [58]. Regardless of
mechanism, this disproportionate CMV cellular reactivity during
antiretroviral therapy is likely to be associated with harm, as we
have recently demonstrated [9] and has been extensively
demonstrated in the very old. Future longitudinal studies to
determine whether CMV drives early immunosenescence during
HIV disease are warranted.
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